- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 2.2 EX-2.2
- 4.21 EX-4.21
- 4.22 EX-4.22
- 4.23 EX-4.23
- 4.24 EX-4.24
- 4.25 EX-4.25
- 4.26 EX-4.26
- 4.27 EX-4.27
- 4.28 EX-4.28
- 4.29 EX-4.29
- 4.30 EX-4.30
- 4.31 EX-4.31
- 4.32 EX-4.32
- 8.1 EX-8.1
- 12.1 EX-12.1
- 12.2 EX-12.2
- 13.1 EX-13.1
- 13.2 EX-13.2
- 15.1 EX-15.1
- Download Excel data file
- View Excel data file
Exhibit 13.1
Certification by the Chief Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the annual report of Mereo BioPharma Group plc (the “Company”) on Form 20-F for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Denise Scots-Knight, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 31, 2021
By: | /s/ Denise Scots-Knight, Ph.D. | |
Name: | Denise Scots-Knight, Ph.D. | |
Title: | Chief Executive Officer |